Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports

OBJECTIVE: Describe available data on birth defects and pregnancy loss in women with systemic lupus erythematosus (SLE) exposed to belimumab. METHODS: Data collected from belimumab clinical trials, the Belimumab Pregnancy Registry (BPR), and postmarketing/spontaneous reports up to 8 March 2020 were...

Descripción completa

Detalles Bibliográficos
Autores principales: Petri, Michelle, Landy, Helain, Clowse, Megan E B, Gemzoe, Kim, Khamashta, Munther, Kurtinecz, Milena, Levy, Roger A, Liu, Andrew, Marino, Rebecca, Meizlik, Paige, Pimenta, Jeanne M, Sumner, Kelsey, Tilson, Hugh, Connolly, Mary Beth, Wurst, Keele, Harris, Julia, Quasny, Holly, Juliao, Patricia, Roth, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887359/
https://www.ncbi.nlm.nih.gov/pubmed/36198440
http://dx.doi.org/10.1136/ard-2022-222505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887359/
https://www.ncbi.nlm.nih.gov/pubmed/36198440
http://dx.doi.org/10.1136/ard-2022-222505

Ejemplares similares